PT  - JOURNAL ARTICLE
AU  - Qin, Vicky Mengqi
AU  - Zhang, Yuting
AU  - Chia, Kee Seng
AU  - McPake, Barbara
AU  - Zhao, Yang
AU  - Hulse, Emily
AU  - Legido-Quigley, Helena
AU  - Lee, John Tayu
TI  - Trends and Variation in User Fees across Provinces in China: a Population-based Longitudinal Data Analysis from 2011-2015
AID  - 10.1101/2020.06.15.20131813
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.06.15.20131813
4099  - http://medrxiv.org/content/early/2020/06/17/2020.06.15.20131813.short
4100  - http://medrxiv.org/content/early/2020/06/17/2020.06.15.20131813.full
AB  - Objectives Understanding the variation in user fees is essential for the design of targeted health financing strategies and monitoring progress towards universal health coverage. This study examines user fees in terms of: (1) temporal trends in cost sharing and out-of-pocket payment (OOPs); (2) factors associated with cost sharing and OOPs; and (3) the relationships between province-level economic development and cost sharing and OOPs in China.Setting 28 provinces of ChinaParticipants A total of 10316 elderly aged ≥45 years were included in the analysis.Results Overall, there were no substantial changes in cost sharing, but the OOPs continued to rise among the middle-aged and older Chinese. Cost sharing was substantially higher for outpatient than inpatient care (84.0% vs 69.2% in 2011; 80.8% vs 62.2% in 2015), and the majority paid more than 80% of the total cost for prescription drugs when visiting outpatient or inpatient care. Provinces with higher GDP per capita tend to have lower cost sharing and a higher OOPs than their counterparts, but the relationship for OOPs became insignificant after adjusting for individual factors. Respondents with health insurance and older age were associated with lower cost sharing. The respondents with higher socioeconomic status and a higher number of chronic conditions incurred higher OOPs for outpatient and inpatient utilisation.Conclusion Cost sharing and OOPs remain very high despite near-universal insurance coverage. Health financing reforms should prioritise improving health services coverage and reducing cost sharing to improve financial protection and reduce health inequalities. Although such improvement will likely have the greatest benefits for financial protection for populations from less developed regions, developed provinces with a higher OOPs will benefit as well.STRENGTHS AND LIMITATIONS OF THIS STUDYThis is the first longitudinal study to measure the trend of and variation in patient cost sharing and OOPs in China.User fees was self-reported by the respondents, which may be subject to recall bias.User fees in this study only reflected the general cost burden from formal healthcare services, therefore, user fees from informal care services were not captured.KEY FINDINGThere were no substantial changes in patient cost sharing for outpatient and inpatient services, but the amount of out-of-pocket payment (OOPs) continued to rise during 2011-2015, especially for outpatient services from 371 Yuan in 2011 to 1031 Yuan in 2015.Despite universal health insurance coverage, patient cost sharing was still high among the middle-aged and older Chinese: 84.0% for outpatient care and 69.2% for inpatient care in 2011; and 80.8% vs 62.2% in 2015. The majority of patients paid more than 80% of the total cost for prescription drugs when visiting outpatient or inpatient care.Several patient-level characteristics affected cost-sharing and OOPs, including insurance status, age, education, household economic status and number of chronic conditions. Cost sharing was lower for those with insurance compared to those without insurance.Provinces with higher GDP per capita had lower cost sharing than provinces with lower GDP per capita, but no significant difference was found in the amount of OOPs after controlling for individual-level factors.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNone.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:CHARLS was approved by the Ethical Review Committee (IRB) at Peking University, Beijing, China.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is publicly available and can be found via http://charls.pku.edu.cn/index/en.htmlGDPgross domestic productNCDnon-communicable diseasesNCMSnew cooperative medical schemeOOPsout-of-pocket paymentUEBMIurban employee basic medical insuranceURBMIurban resident basic medical insurance